HIND logo

VYOME HOLDINGS INC

HINDNASDAQ
🏆 #4886 by market capEarnings Nov 12US Equity
$2.02▼ $0.04 (−1.94%)
🌙 After hours$2.10▲ 3.96%Regular close · extended-hours price shown
🔔
Track HIND
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.9%
7d▼ 2.4%
14d▼ 0.5%
30d▼ 9.0%
ytd▼ 41.3%
1y▼ 62.5%
🏦Market Cap
$14M
Small Cap
📈Revenue Growth (YoY)
-96.0%
Declining
📊Gross Margin
46.5%
Healthy
💵FCF Margin
404.3%
Strong
⚖️P/S Ratio
109.8x
Expensive
Otter Score
72
Fair

Trading Snapshot

Day Range
$2.00 – $2.06
52-Week Range
$1.75 – $6.56
Volume
$2.41B
Avg Volume
$2.96B
Shares Outstanding
7.0M
Next Earnings
Dec 14, 2026

Fundamentals Snapshot

Annual Revenue
$319,714
Last Q Revenue
$26,955
P/E Ratio
-0.1
P/S Ratio
109.8x
EPS (TTM)
$-1.61
Dividend Yield
0.00%
Dilution (1yr)
+20172.4%

Why Investors Own HIND

  • ✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 54% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HIND logo

VYOME HOLDINGS INC

HIND
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$320K▼ −96.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.7%▲ +2.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▼ −64.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −15.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
5.9M▲ +20172.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$5M YoY
StockOtter · stockotter.space

About VYOME HOLDINGS INC

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$2.04
▲ +1.2% Upside
High Target$2.31
Low Target$1.71
Based on 11 analysts

Latest News & Updates

Business Wire·15d ago

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #CFO--Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-infla

Business Wire·Aug 25

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial re

Business Wire·Jul 1

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-in